Medical treatment of non-small cell lung cancer:An update / 医学研究生学报

ABSTRACT

Non-small cell lung cancer ( NSCLC) is the most common histological type and accounts for approximately 80%-85%of lung cancers , which can be classified into lung adenocarcinoma , squamous cell carcinomas , and so on.With the coming era of precise treatment, NSCLC is further divided into treatable oncogenic alterations negative-and positive-NSCLC.For patients without treatable oncogenic alterations , platinum-based chemotherapy remains the cornerstone of the treatment , and antiangiogenesis therapy al-so plays an important role in the subsequent treatment .For those with treatable oncogenic alterations , in addition to standard first gener-ation EGFR-TKIs and ALK-TKIs, second and third generation targeted drugs have been investigated in first line or post -resistance treat-ment.The application of immune checkpoint inhibitors has become a new trend of lung cancer treatment .Our review summarizes recent advances in chemotherapy , antiangiogenesis therapy ,target therapy , and immunotherapyof NSCLC .